Vivani Medical Reports Q1 Results, Secures $9.7M Capital, Extends Runway to Mid-2027, and Advances SLIM-1 Clinical Trial

summarizeSummary

Vivani Medical reported its first-quarter 2026 financial results, including an increased net loss but an improved per-share loss, while successfully raising $9.7 million to extend its cash runway through mid-2027. The company also confirmed its lead clinical trial is on track and is pursuing a spin-off of its neuromodulation subsidiary, Cortigent.

check_boxKey Events

• First Quarter 2026 Financial Results

  Vivani Medical reported a net loss of $6.8 million for Q1 2026, compared to $6.3 million in Q1 2025. However, net loss per common share improved to $(0.08) from $(0.11) year-over-year.

• Extended Cash Runway

  The company holds $28 million in cash, cash equivalents, restricted cash, and capital commitments as of March 31, 2026, expected to fund operations through the first half of 2027.

• Successful Capital Raise

  Vivani raised $9.7 million in financing activities during Q1 2026, including $2.2 million from a registered direct offering and $7.6 million from other securities purchase agreements.

• Clinical Trial Progress

  Initiation of the SLIM-1™ clinical trial, a Phase 1 study of its NPM-139 semaglutide implant for chronic weight management, is on track for mid-year 2026, with top-line results anticipated by year-end.

auto_awesomeAnalysis

This filing provides a comprehensive update on Vivani Medical's financial health and pipeline progress. The successful capital raise of $9.7 million in Q1 significantly bolsters the company's cash position, extending its operational runway through the first half of 2027. This financial stability is critical for a clinical-stage biopharmaceutical company, enabling it to fund ongoing research and development. The confirmation that the SLIM-1 Phase 1 clinical trial is on track for mid-year initiation, with results expected by year-end, is a key value driver for the company's lead semaglutide implant program. Additionally, plans to spin off Cortigent Inc. could unlock further value for shareholders.